

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Shaw-Fen Sylvia Hu

Serial No.:

To Be Assigned

Filed:

October 13, 2000

For:

Truncated Glial Cell Line-Derived Neurotrophic Factor

Docket No.:

A-357C

ATTORNEY'S STATEMENT PURSUANT TO 37 C.F.R. 1.821(e)

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

The computer readable form in this Application, is identical with that filed in Application Number 08/535,681; filed September 28, 1995. The present application is a divisional of application Serial No. 08/535,681. In accordance with 37 CFR 1.821(e), please use the last-filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included for incorporation into the specification.

In addition to (1) the paper copy included in the instant application and (2) the reference to the other application and computer readable form, the undersigned verifies that the content of the paper copy in the instant application is identical to the computer readable form filed in Application Number 08/535,681.

Respectfully submitted,

Smial R. Cm

Daniel R. Curry

Attorney for Applicant

Registration No.:

32,7270

Phone: (805) 447-8102

Date October 13, 2000

Please send all future correspondence to:

U.S. Patent Operations/DRC
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number:	EL360689271US	Date of Deposit:	October 13, 2000	
indicated above and is addressed to Box	eing deposited with the United States Pos Patent Application, Assistant Commissio	stal Service "Express Mail Posiner for Patents, Washington, I	1. Office to Addressee* sen 0.C. 20231. Signature	ren